WuXi Global Forum 2022

Dear colleagues and friends, 

On Jan 10, the much anticipated 10th annual WuXi Global Forum will once again unite thousands of colleagues around the world which we will premiere twice to accommodate global time zones. In this special 10-year edition, we will focus on “Impact.” What impact have we had on our patients during the past 10 years? How will technologies shape breakthroughs in the next decade? What can we do collectively and collaboratively to make a bigger social impact for patients around the world?

MORNING AGENDA (Pacific Standard Time on Jan 10, 2022 | Digital Global Program)   

8:00 – 8:05          Welcome

 Hui
Cai, Program Chair,
VP and Head of Content, WuXi AppTec

8:05 – 8:10         Opening Remarks

Minzhang Chen, Co-CEO,
WuXi AppTec

8:10 – 8:45         Opening Plenary: Changing the Games
of R&D Productivity
David Berry, Founder and CEO, Valo
Health
Diego Miralles, CEO, Laronde

Roger
Perlmutter, Chairman & CEO, Eikon Therapeutics
Henrijette Richter, Managing
Partner, Sofinnova Partners
Session Leader: Jorge Conde,
General Partner, Andreessen Horowitz 

8:45 –
9:10         A Special Tribute to Dr. José Baselga

A Conversation between Susan Galbraith, EVP, Oncology R&D,
AstraZeneca and David Reese, EVP of
R&D, Amgen

9:10 –
9:30         A Special Tribute to Dr. Tachi Yamada

A Conversation with James Wilson, Professor of Medicine and Pediatrics of Department of Medicine, and Director
of Gene Therapy Program, University of Pennsylvania. Moderated by John Carroll, Chief Editor &
Founder, Endpoints News

9:30 –
10:10       Investing for Social
Impact
Christiana Bardon, Co-Managing Partner of BioImpact Capital, MPM
Capital
Jürgen Eckhardt, SVP and Head of
Leaps by Bayer
Alice Pomponio, Managing Director, American
Cancer Society BrightEdge
Glenn Rockman, Founder and Managing
Partner, Adjuvant Capital
Session
Leader: Laura Kleiman, Founder
and CEO, Reboot Rx

 10:10 – 10:50   Delivering on the Promise of New Modalities
Debora Barton, CMO, Carisma Therapeutics
John Houston, President and CEO,
Arvinas
Eric Kelsic, Founder & CEO, Dyno
Therapeutics
Devyn Smith, CEO, Arbor
Biotechnologies
Session Leader: Ryan Cawood, CSO, WuXi
Advanced Therapies and OXGENE

10:50 –
11:10    Closing Keynote

A Conversation with Todd Golub,
Director, Broad Institute of MIT & Harvard. Moderated by Kevin Davies,
Executive Editor, The CRISPR Journal and GEN Biotechnology; and Author, Editing
Humanity